All updated as on -
The global hyperphosphatemia market is expected to expand from $2.7 billion in 2022 to $4.3 billion in 2030, representing a compound annual growth rate (CAGR) of 6.6% over the forecast period. When there is an excessive amount of phosphate in the blood, a condition known as hyperphosphatemia occurs. Patients with chronic renal failure and cardiovascular illnesses have been found to have abnormally high amounts of phosphate. Hyperphosphatemia is associated with an increased risk of death and complications in people with chronic renal disorders. Mental confusion, a lack of appetite, bone discomfort, and even bone fractures are all signs of hyperphosphatemia, a condition in which the body contains an excessive amount of phosphates. Phosphate is found in all of the body's fluids, including blood, cells, bones, and teeth. In addition, adequate phosphate levels in the body are essential for proper kidney function. However, excessive blood phosphate levels can be the result of renal impairment brought on by disease or their effects. Chronic renal disease, often known as end-stage kidney disease, is linked to high phosphate levels in the blood. Hyperphosphatemia can be caused by a number of factors, including low parathyroid hormone levels, uncontrolled diabetes, excessive vitamin D levels, and diabetic ketoacidosis.
The rising global incidence of chronic renal illness is one of the primary drivers of market growth. The current pace of increase in the prevalence of chronic kidney disease (CKD) is expected to quicken in the coming years. This will remain a leading cause of death worldwide for the foreseeable future. In 2018, the National Kidney Foundation Inc. reported that 7.85 million Americans were either dialysis patients or kidney transplant recipients. Most dialysis patients developed hyperphosphatemia after a certain length of time on the treatment. Hyperphosphatemia is treated with phosphate binders in 80% to 85% of dialysis patients, according statistics provided by the National Centre for Biotechnology Information (NCBI). The rising prevalence of kidney failure is predicted to fuel industry growth.
Report Coverage
Global Hyperphosphatemia research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Hyperphosphatemia report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Hyperphosphatemia competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Hyperphosphatemia market players and analyses their core competencies in each global market sub-segments.
Market Factors That Matter
The rising global incidence of chronic renal illness is one of the primary drivers of market growth. The current pace of increase in the prevalence of chronic kidney disease (CKD) is expected to quicken in the coming years. This will remain a leading cause of death worldwide for the foreseeable future. In 2018, the National Kidney Foundation Inc. reported that 7.85 million Americans were either dialysis patients or kidney transplant recipients. Most dialysis patients developed hyperphosphatemia after a certain length of time on the treatment. Hyperphosphatemia is treated with phosphate binders in 80% to 85% of dialysis patients, according statistics provided by the National Centre for Biotechnology Information (NCBI). The rising prevalence of kidney failure is predicted to fuel industry growth. The launch of more products in emerging countries is anticipated to boost growth in the worldwide hyperphosphatemia market. Example: In April of 2021, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) revealed encouraging results from a phase III research in China for Velphoro (PA21) to reduce serum phosphorous in the elderly. In addition, in July of 2020, Emcure Pharmaceuticals introduced the first generic form of sucroferric oxhydroxide (Dynulta) to the Indian market. Consequently, the approval of more products will fuel market growth in developing nations.
Restrictive Conditions
Market growth is being stymied in large part because dialysis patients aren't sticking to their treatment plans. The National Centre for Biotechnology Information (NCBI) reports that the high number of drugs (up to 12) required by dialysis patients can lead to gastrointestinal discomfort. The number of people with CKD who take phosphate binders will go down as a result of these variables.
Possibilities and Dangers in the Market
Excessive phosphate levels have been related to serious health issues such kidney issues and diabetes, according to prior research. Despite projections of high growth, hyperphosphatemia will be challenging to manage due to factors like insufficient knowledge of the problem, rising competition among market competitors, and insufficient knowledge of how phosphate is handled in food products.
Crucial Commercial Window of Opportunity
As a result of recent technological advancements in the industry, an increasing number of businesses have entered the hyperphosphatemia market, increasing competition among these businesses. To maintain their competitive edge, businesses are pouring significant resources into research and development. Among the many medical issues that Shield Therapeutics wants to treat with future drug developments are hyperphosphatemia and iron deficient anaemia. The company's flagship product is called Feraccru. The PT30 product line also includes an IV iron therapy option that does not pose an allergy risk, which was issued by the business.
Information and Research on Products
The major product categories of the global hyperphosphatemia market include segelamer, calcium-based phosphate binders, iron-based phosphate binders, non-phosphate binders, lanthanum carbonate, and others. During the anticipated period, the sevelamer category is anticipated to keep its leading position in the market share rankings. The increasing prevalence of renal diseases is anticipated to be one of the main factors of market revenue expansion. The medicine has been well-received by both groups, increasing the scope of its applications. Patients on haemodialysis and those with chronic renal illness are two groups that benefit from its therapeutic application.
Information and Analysis of the Distribution Network.
The global hyperphosphatemia market can be divided into three submarkets: hospitals and clinics, online pharmacies, and conventional brick-and-mortar drugstores. The hospital pharmacy sector is estimated to lead the market with the largest market share over the forecast period as a result of the increasing number of patients seeking dialysis in hospitals around the world. The demand for dialysis services has also skyrocketed in emerging economies like China and India. This causes progress to occur in distinct phases.
Regional Viewpoints
The ageing population and rising prevalence of chronic renal illness in North America predict a sizable demand for hyperphosphatemia-targeting pharmaceuticals in the region. Several major countries in North America, including the United States, Canada, and Mexico, all make important contributions to this sector. Asia Pacific countries including China, Japan, and India are anticipated to have the fastest-growing hyperphosphatemia medicine market. Growth is forecast for a number of European economies, including Germany, Italy, and France. Hyperphosphatemia medications are not expected to do well in the Middle East and Africa due to low healthcare spending, a lack of public knowledge, and a focus on treating patients based on their individual conditions. Major economic contributions in this region include countries like Saudi Arabia, South Africa, and the United Arab Emirates.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Hyperphosphatemia market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Hyperphosphatemia market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Hyperphosphatemia market based on the below-mentioned segments:
Global Hyperphosphatemia Market, By Type
Global Hyperphosphatemia market, By Distribution
Global Hyperphosphatemia market, Regional Analysis
The rising global incidence of chronic renal illness is one of the primary drivers of market growth. The current pace of increase in the prevalence of chronic kidney disease (CKD) is expected to quicken in the coming years. This will remain a leading cause of death worldwide for the foreseeable future. In 2018, the National Kidney Foundation Inc. reported that 7.85 million Americans were either dialysis patients or kidney transplant recipients. Most dialysis patients developed hyperphosphatemia after a certain length of time on the treatment. Hyperphosphatemia is treated with phosphate binders in 80% to 85% of dialysis patients, according statistics provided by the National Centre for Biotechnology Information (NCBI). The rising prevalence of kidney failure is predicted to fuel industry growth.
Report Coverage
Global Hyperphosphatemia research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Hyperphosphatemia report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Hyperphosphatemia competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Hyperphosphatemia market players and analyses their core competencies in each global market sub-segments.
Market Factors That Matter
The rising global incidence of chronic renal illness is one of the primary drivers of market growth. The current pace of increase in the prevalence of chronic kidney disease (CKD) is expected to quicken in the coming years. This will remain a leading cause of death worldwide for the foreseeable future. In 2018, the National Kidney Foundation Inc. reported that 7.85 million Americans were either dialysis patients or kidney transplant recipients. Most dialysis patients developed hyperphosphatemia after a certain length of time on the treatment. Hyperphosphatemia is treated with phosphate binders in 80% to 85% of dialysis patients, according statistics provided by the National Centre for Biotechnology Information (NCBI). The rising prevalence of kidney failure is predicted to fuel industry growth. The launch of more products in emerging countries is anticipated to boost growth in the worldwide hyperphosphatemia market. Example: In April of 2021, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) revealed encouraging results from a phase III research in China for Velphoro (PA21) to reduce serum phosphorous in the elderly. In addition, in July of 2020, Emcure Pharmaceuticals introduced the first generic form of sucroferric oxhydroxide (Dynulta) to the Indian market. Consequently, the approval of more products will fuel market growth in developing nations.
Restrictive Conditions
Market growth is being stymied in large part because dialysis patients aren't sticking to their treatment plans. The National Centre for Biotechnology Information (NCBI) reports that the high number of drugs (up to 12) required by dialysis patients can lead to gastrointestinal discomfort. The number of people with CKD who take phosphate binders will go down as a result of these variables.
Possibilities and Dangers in the Market
Excessive phosphate levels have been related to serious health issues such kidney issues and diabetes, according to prior research. Despite projections of high growth, hyperphosphatemia will be challenging to manage due to factors like insufficient knowledge of the problem, rising competition among market competitors, and insufficient knowledge of how phosphate is handled in food products.
Crucial Commercial Window of Opportunity
As a result of recent technological advancements in the industry, an increasing number of businesses have entered the hyperphosphatemia market, increasing competition among these businesses. To maintain their competitive edge, businesses are pouring significant resources into research and development. Among the many medical issues that Shield Therapeutics wants to treat with future drug developments are hyperphosphatemia and iron deficient anaemia. The company's flagship product is called Feraccru. The PT30 product line also includes an IV iron therapy option that does not pose an allergy risk, which was issued by the business.
Information and Research on Products
The major product categories of the global hyperphosphatemia market include segelamer, calcium-based phosphate binders, iron-based phosphate binders, non-phosphate binders, lanthanum carbonate, and others. During the anticipated period, the sevelamer category is anticipated to keep its leading position in the market share rankings. The increasing prevalence of renal diseases is anticipated to be one of the main factors of market revenue expansion. The medicine has been well-received by both groups, increasing the scope of its applications. Patients on haemodialysis and those with chronic renal illness are two groups that benefit from its therapeutic application.
Information and Analysis of the Distribution Network.
The global hyperphosphatemia market can be divided into three submarkets: hospitals and clinics, online pharmacies, and conventional brick-and-mortar drugstores. The hospital pharmacy sector is estimated to lead the market with the largest market share over the forecast period as a result of the increasing number of patients seeking dialysis in hospitals around the world. The demand for dialysis services has also skyrocketed in emerging economies like China and India. This causes progress to occur in distinct phases.
Regional Viewpoints
The ageing population and rising prevalence of chronic renal illness in North America predict a sizable demand for hyperphosphatemia-targeting pharmaceuticals in the region. Several major countries in North America, including the United States, Canada, and Mexico, all make important contributions to this sector. Asia Pacific countries including China, Japan, and India are anticipated to have the fastest-growing hyperphosphatemia medicine market. Growth is forecast for a number of European economies, including Germany, Italy, and France. Hyperphosphatemia medications are not expected to do well in the Middle East and Africa due to low healthcare spending, a lack of public knowledge, and a focus on treating patients based on their individual conditions. Major economic contributions in this region include countries like Saudi Arabia, South Africa, and the United Arab Emirates.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Johnson and Johnson, Amag Pharmaceuticals, Keryx Biopharmaceuticals, DSM Biotech Pharmacal, Sun Pharm Inc., Zeria Pharmaceutical, Bruno Pharmaceutical Spa, Fermenta Biotech Ltd, Pfizer Inc., Roche Diagnostics Corporation |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Hyperphosphatemia Market from 2021 to 2030.
- Market Forecast for Hyperphosphatemia Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Hyperphosphatemia competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Hyperphosphatemia
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Hyperphosphatemia market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Hyperphosphatemia market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
- Amag Pharmaceuticals
- Johnson and Johnson
- Keryx Biopharmaceuticals
- DSM Biotech Pharmacal
- Sun Pharm Inc.
- Zeria Pharmaceutical
- Bruno Pharmaceutical Spa
- Fermenta Biotech Ltd
- Pfizer Inc.
- Roche Diagnostics Corporation
Primary Target Market
- Market Players of Hyperphosphatemia
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Hyperphosphatemia market based on the below-mentioned segments:
Global Hyperphosphatemia Market, By Type
- Sevelamer
- Calcium based phosphate binder
- Iron based phosphate binders
- Lanthanum carbonate
- Non phosphate binders
- Others
Global Hyperphosphatemia market, By Distribution
- Hospital pharmacy
- Retail pharmacy
- Online stores
Global Hyperphosphatemia market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive hyperphosphatemia market market research and competitor analysis for your business to help you develop more profound insights into the hyperphosphatemia market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the hyperphosphatemia market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.